Mental health disorders have been found to be three to five times more prevalent in children and adolescents with intellectual disability compared with their typically developing peers.\(^1\)\(^2\) Consistent with this general mental health inequity, adolescents with intellectual disability, Autism Spectrum Disorder (hereafter referred to as autism) or both conditions are at higher risk for depression than their peers of a similar age.\(^3\)\(^4\)\(^6\) Specifically, children and young people with intellectual disability are 1.7 times more likely to experience depression compared with other children.\(^5\) Although young people with autism have demonstrated higher rates of depression than typically developing children and adolescents, reported rates vary considerably.\(^6\)

Treatment for mental health problems in people with intellectual disability has historically relied on pharmacological approaches.\(^7\)\(^8\) However, international guidelines and recommendations suggest that first-line treatments for depression in children and young people should include psychological therapies.\(^9\)\(^10\) There is some support for the use of cognitive–behavioural therapy (CBT) for depression in adults with mild-to-moderate intellectual disability,\(^7\) but a lack of research for children and adolescents. Research evidence for the psychological treatment of depression in children and adolescents with autism is available now.\(^11\)\(^12\) The current study, therefore, had three review questions. First, what is the current evidence base for psychological interventions for depression in children and young people with intellectual disability and/or autism? Second, what are the experiences of children and young people with intellectual disability and/or autism and their family members of psychological intervention for depression? And finally, what are the experiences of therapists delivering psychological intervention for depression to children and young people with intellectual disability and/or autism?

### Method

The review protocol was prospectively registered with the International Prospective Register of Systematic Reviews (registration number CRD42019145495; https://www.crd.york.ac.uk/Prospero/display_record.php?ID=CRD42019145495). The review was conducted and is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.\(^13\)

**Search strategy**

PsycINFO, Medline, EMBASE via Elsevier, CINAHLPlus, Social Sciences Index and Sciences Index via Web of Science, and Scopus databases were searched by two authors (L.A.C and K.P.) on 1 May 2020 for articles published from inception to 30 April 2020. Searches were conducted with keywords identified for each domain (see Table 1 for an example search string) and limited to articles written in English. Hand searching of reference lists and
Table 1  Search terms

| Domain                                      | Search terms                                                                 |
|---------------------------------------------|-----------------------------------------------------------------------------|
| Age group                                  | adolescents* OR teen* OR youth OR child* OR 'young person' OR juvenile OR pediatric |
| Intellectual disability and/or autism       | (mental* AND handicap* OR retard* OR disab* OR impair* OR deficit*) OR (learning OR intellect* OR development*) AND (difficult* OR disab* OR impair* OR disorder* OR handicapt*) OR (Down* OR 'Smith-Magenis' OR Rett* OR 'Lesch-Nyhan' OR Prader Willi OR Angelman OR 'Fragile X' OR 'Cri-du-chat' OR Cornelia de Lange OR 'de Lange' OR 'Rubenstein-Taybi' OR velocardiofacial) AND syndrome*/ OR (moron OR imbecile OR feeble-minded) OR (autis* OR ASD OR Asperger*) (depress* AND symptom* OR disorder OR thought* OR behavi* OR (affective OR mood* OR emotion*) AND (disorder OR symptom* OR disturb*) OR (depression OR dysthy* OR melancholy*) |
| Treatment or intervention                  | therap* OR treat* OR intervention OR management OR counsel* OR training OR case OR psychotherap* |

Inclusion/exclusion criteria

Studies were included if they met the following criteria.

Study design

Pre–post single-group designs, case series, clinical case reports, single-case experimental designs and qualitative studies. Studies with a comparison group, control group or no control group were all included. Observational and case-control studies involving no treatment were excluded.

Participants

Children, adolescents or young people up to 21 years of age, with an intellectual disability (including borderline intellectual disability) and/or autism. Studies were included if the entire sample included the relevant population, or if outcomes were reported separately for the relevant population. Studies that involved young people up to the age of 25 years were included if 75% of the sample was under 21 years of age.

Participant diagnosis

Either (a) major depressive disorder as diagnosed by standardised criteria (e.g. the DSM, ICD, Diagnostic Manual-Intellectual Disability); (b) dysthymia or minor depression as diagnosed by standardised criteria; or (c) depressive status, as defined by meeting cut-offs on a standardised depression screening questionnaire (e.g., Children’s Depression Inventory (CDI),14 Beck Depression Inventory (BDI-II),15 Glasgow Depression Scale16).

Treatment or intervention

Any psychological or psychosocial intervention (e.g. life skills training, lifestyle intervention) with the aim of treating depression or depressive symptoms. Pharmacological or medical treatments, transcranial magnetic stimulation, complementary and alternative therapies and treatments were excluded.

Screening

First-stage title and abstract screening was undertaken by two authors (L.A.C. and K.P.) to identify any articles that were clearly not relevant to the review, with a randomly selected 20% screened by both authors to determine interrater reliability. Agreement was 99.1% (κ=0.940). Full-text review was independently undertaken by the same two authors, with any conflicts of inclusion/exclusion resolved through discussion, and consultation with additional authors (K.M.G. and G.A.M.) where necessary (n = 1).

Data extraction

Data were extracted from each article and coded for (a) study information (type of study, country of publication, year of publication), (b) participant information (age, gender, intellectual disability/autism diagnosis), (c) assessment of depression, (d) treatment information (type of treatment/intervention, length of treatment, length of follow-up) and (e) study outcomes.

Risk of bias

Risk of bias assessments were conducted by a panel of four authors (L.A.C., K.P., G.A.M. and K.M.G.). Assessments of controlled and uncontrolled trials were conducted using predeveloped proformas based on the Cochrane risk of bias tool and the Newcastle–Ottawa Scale.7,16 These proformas have been used previously in large, international systematic reviews such as that by Blackmore et al.18 Single case studies and case series were appraised with the criteria described by Horner et al.20 Each study was assessed overall as being of low, moderate or high risk of bias.

Results

A total of 13 936 records were retrieved in the search. After removal of duplicates, 9343 records remained for abstract and title screening. A further 9231 records were excluded, leaving 114 for full-text review. No additional articles were identified through reference lists of included studies or forward citation searching. A total of 10 studies met inclusion criteria (Fig. 1).

Summary data for all included studies, including sample description, assessment of depression, description of treatment and treatment duration, outcome measures and study results related to the effect of treatment on depression or depressive symptoms, can be viewed in Tables 2 and 3.

Research question 1: what is the evidence base for psychological interventions for depression for children and young people with intellectual disability and/or autism?

Of the ten included studies, four were clinical case reports,21,23,26,28 and the remaining six were experimental or quasi-experimental designs, including one multiple baseline design study,33 two uncontrolled group design trials36,39 and three controlled group design trials.44,48,51

Clinical case reports

Across the four clinical case reports, five participants were described (n = 3 male, ages ranging from 12 to 18 years). One clinical case report used a combination of psychotherapy and behavioural training to target depressive symptoms in a 17-year-old female with a mild intellectual disability.21 Three clinical case reports used...
adapted versions of CBT with a 12-year-old male, a 17-year-old female, and two males aged 17 and 18 years old, all with Asperger syndrome.

Three clinical case reports utilising CBT adapted their programme for young people with autism. Greig and MacKay highlight that their CBT programme, The Homunculi, involves the creation of characters to help the individual to visualise various processes and behaviours. Loades reported that the CBT programme was adapted for their participant with Asperger syndrome, but did not describe what these adaptations involved. Selvapandiyan implemented pragmatic CBT, described by the author as being designed to target the social communication difficulties evident in Asperger syndrome. The duration of treatment varied across the clinical case reports, ranging from 15 individual sessions to 8 months. Behavioural training was more intensive, with sessions being undertaken almost daily, whereas CBT was undertaken weekly. Behavioural training in these instances involved behavioural modification of identified behaviours, including adherence, lack of interest, oppositional behaviours and self-harm.

Three clinical case reports relied on questionnaires to assess change in depressive symptoms over the course of treatment. One clinical case report used the depression scale of the Briere Trauma Scales (self-report) pre- and post-treatment. Another clinical case report used the Revised Children’s Anxiety and Depression Scales (self-report) at pre-treatment and throughout the course of treatment at sessions at 6, 12 and 20 weeks. The remaining clinical case report used the Hamilton Rating Scale for Depression (HRSD), rated by the clinician at the end of each treatment session. The study reported that progress was monitored over 2 months post-treatment; however, the HRSD scores at follow-up were not reported.

All clinical case reports reported an improvement in depressive symptoms following the intervention, whether that was a decrease in problem behaviours or a reduction in depressive scores on screening measures. Maintenance of improvements were reported for the one clinical case report that included longer term follow-up. Two of the clinical case reports reported the use of medication throughout the study period; one introduced medication (olanzapine and chlorpromazine) at the beginning of the treatment period, and the other reported that the client had been prescribed medication 10 weeks before the commencement of the CBT intervention, with a stable dose maintained throughout the intervention programme. Neither study considered the potential effects of the medication when reporting treatment outcomes.
| Author, year, country | Sample size and description | Assessment of depression | Treatment | Duration of treatment | Outcome measures | Results | Risk of bias |
|-----------------------|-----------------------------|--------------------------|-----------|----------------------|-----------------|---------|-------------|
| Fernandez et al, 2005, USA | N = 1, female, 17 years old, mild intellectual disability | Clinical intake interview: major depression (DSM-IV) | Psychotherapy (weekly): relaxation exercises, responding empathetically and assistance with reframing. Therapeutic behavioural treatment (25–35 h per week) occurred both at school and group home. Medication: olanzapine and chlorpromazine introduced at the beginning of treatment; olanzapine continued throughout treatment, fluoxetine replaced chlorpromazine at 7 months | 8 months | Observation of target behaviours: adherence, lack of interest, oppositional behaviours and self-harm. Number of times each behaviour occurred within the observational period was recorded monthly | Psychotherapy: improved coping skills, improvement in ability to express feelings and improved capacity for self-advocacy. Behavioural treatment: decrease in frequency of maladaptive (target) behaviours, recurrence of oppositional behaviours in last 2 months of treatment. Improvement in GAF (DSM-IV) score from 25 (beginning of treatment) to 40 (end of treatment) | High |
| Greig and MacKay, 2005, USA | N = 1, male, 12 years old, Asperger syndrome, WISC-III FSIQ = 118 | Clinically significant scores on self-report measure: Brie Trauma Scales, depression scale | CBT (The Homunculi): a meta-cognitive visual aid using development of characters to support the use of tools to improve targeted behaviours, specifically developed by authors for people with autism | 15 sessions | Measured post-intervention. Emotional state: anxiety, depression, anger and stress scales of the Brie Trauma Scales. Social competence and social skills: assessment by parent and self-report. School adjustment: teacher feedback | Emotional state on all scales, including depression, reduced to lower than clinically significant levels and were at the mean for the participant’s age group. Improvements in perceived social competence and social skills, although still at lower levels than same-aged peers. Reduction in concerns expressed by teacher about school adaptation | High |
| Loades, 2015, USA | N = 1, female, 17 years old, Asperger syndrome | Clinically significant score on self-report measure: Revised Children’s Anxiety and Depression Scale (RCADS) (T score of 85) | CBT for low self-esteem, with adaptations made for autism, although what adaptations were made was not reported (weekly sessions). Medication: antidepressant medication prescribed 10 weeks before commencement of therapy and continued throughout | 20 sessions | Progress assessments at session 6, session 12 and session 20. RCADS scores (T scores on depression, overall anxiety and specific anxiety subscales) | Clinically significant reduction in anxiety and depression at the end of treatment. Depression subscale score just below clinical range at end of treatment | High |
| Selvapandiyan, 2019, India | N = 2, male, 17 years old; male, 18 years old, Asperger syndrome | Clinical interview: depressive disorder (ICD-10-DCR) | Pragmatic CBT (specifically adapted for Asperger syndrome to focus on difficulties with social communication) with acceptance and mindfulness techniques weekly, 60-min sessions). Medication: both participants had been treated with psychotropic medication for some months before commencing CBT | 20 weeks | Measured at the end of each session. Additional follow-up period for 2 months post-intervention. Hamilton Rating Scale for Depression and Social Functioning Questionnaire | Both participants saw a reduction in scores on the Hamilton Rating Scale for Depression to below clinically significant levels. Participants remained free from depressive symptoms over the follow-up period. Improvement in scores on Social Functioning Questionnaire at the end of treatment | High |

GAF, Global Assessment of Functioning; WISC, Wechsler Intelligence Scale for Children; FSIQ, Full Scale Intelligence Quotient; CBT, cognitive–behavioural therapy.
| Author, year, country | Sample size and description | Treatment | Control group | Randomisation | Assessment of depression | Treatment | Duration of treatment | Outcome measures | Results | Risk of Bias |
|------------------------|-----------------------------|-----------|---------------|---------------|------------------------|-----------|----------------------|-----------------|---------|--------------|
| Frame et al, 1982, USA | N = 1, male, 10 years old, borderline intellectual disability, WISC-R FSIQ = 79 | N/A | N/A | N/A | Psychiatric interview: major depressive episode (DSM-III) Clinical cut-off met on the parent-report measures CDI, Child Behavior Problem Checklist and Bellevue Index of Depression | Behavioural training (20-min sessions each weekday): instructions, modelling, role-play and performance feedback. Multiple baseline across behaviours design: 8-day pre-treatment baseline for all behaviours, followed by implementation of behavioural training for each target behaviour (first two behaviours introduced simultaneously, followed by the third behaviour and finally, the last behaviour). | 28 sessions | 12-week follow-up after completion of treatment. | Each behaviour improved (i.e. less frequent occurrence) from baseline to when the intervention was introduced. Improvements in behaviour continued to be evident at 12-week follow-up (i.e. frequency of behaviours were still below the baseline rate) | Moderate |
| Dosen, 1984, The Netherlands | N = 31, age 3–16 years, gender not reported, intellectual disability: 32% IQ 30–50, 48% IQ 50–80, 20% IQ 80–90 | N/A | N/A | N/A | Evaluation of symptoms: depression (DSM-III) | Individual psychotherapy based on relationship therapy (frequency not reported; not reported whether adapted for people with intellectual disability). Medication: tricyclic antidepressants prescribed for children who had little to no success with psychotherapy | Approximately 6 months | Clinical judgement on change in symptoms | 87% showed clear clinical improvement on depressive symptoms, impact of medication not reported | High |
| Habayeb et al, 2017, USA | N = 39, 82.1% male, M age = 10 years (s.d. = 1.6 years), autism without intellectual disability | N/A | N/A | N/A | Depression subscale score of BASC-2 overall sample mean clinically significant T score | Resilience Builder Program. Manualised group CBT targeting social competence skills through a broader resilience framework (not an autism specific intervention). 12× 1-h weekly sessions, with 4–6 children in each group | 12 weeks | Measured at the end of the treatment programme. Internalising and externalising symptoms (BASC-2 parent-report) autism-related social and communication impairments (Social Responsiveness Scale, parent-report; Social Communication Questionnaire, parent-report) Positive and negative emotions and emotion control (How I Feel Questionnaire, self-report) | Significant improvement in self-reported emotion control following treatment. No changes in depressive symptoms (measured by the BASC-2 Depression subscale) | High |

(Continued)
| Author, year, country | Sample size and description | Treatment group | Control group | Randomisation | Assessment of depression | Treatment | Duration of treatment | Outcome measures | Results | Risk of Bias |
|-----------------------|----------------------------|-----------------|--------------|---------------|-------------------------|-----------|----------------------|-----------------|---------|-------------|
| McGillivray and Evert, 2014, Australia | \(N = 42, 72\% \text{ male}, M_{\text{age}} = 20.6 \text{ years (s.d. = 4.1 years), range 15–25 years, Asperger syndrome (72\%) and high-functioning autism (28\%)}\) | \(N = 26, 73.1\% \text{ male}, M_{\text{age}} = 20.27 \text{ years (s.d. = 4.39 years)}\) | Waitlist control: \(N = 16, 81.3\% \text{ male}, M_{\text{age}} = 20.50 \text{ years (s.d. = 3.40 years)}\) | Allocation to group according to alternating order of enrolment | Scores above normal range on any of the following: DASS\(^{45}\), ATQ\(^{46}\) and ASSQ\(^{47}\) | Group CBT: ‘Think well, feel well and be well’, developed to address the social difficulties experienced by young people with autism. Weekly, 2-h sessions | 9 weeks | Measured post-treatment, and at 3- and 9-month follow-up. DASS\(^{45}\) total, depression, anxiety and stress subscales, ATQ\(^{46}\) and ASSQ\(^{47}\) | Significant decrease in DASS total and depression subscale scores from pre-to post-treatment, regardless of allocation to treatment or control group. For participants with DASS depression scores above the normal range, a significant decrease on DASS depression scores was found between pre- and post-treatment for those in the treatment group. No differences in DASS depression scores at 3 or 9 months’ follow-up. DASS depression scores at 9 months’ follow-up were significantly lower than at pre-treatment | Moderate |
| Ringenbach et al, 2019, USA | \(N = 49, 59\% \text{ male}, M_{\text{age}} = 18.3 \text{ years (s.d. = 4.1 years), Down syndrome, mean mental age (PPV) of 5.5 years}\) | Assisted cycling therapy (ACT) group: \(N = 10, 45\% \text{ male}\); voluntary cycling group: \(N = 8, 100\% \text{ male}\) | Counterbalanced to ACT or voluntary cycling groups: Control group made of convenience sample | Depressive symptoms assessed by CDI\(^{14}\) | Cycling intervention, 3 × 30-min sessions per week | 8 weeks | Measured pre- and post-treatment: VABS\(^{49}\), CDI\(^{14}\) and Physical Activity Self-Efficacy\(^{50}\) | Participants in the ACT group had greater improvements on CDI scores when compared with the voluntary and no cycling groups. The voluntary and no cycling groups did not differ | Moderate |
| Santomauro et al, 2016, Australia | \(N = 23, 60\% \text{ male}, M_{\text{age}} = 15.75 \text{ years (s.d. = 1.37 years), range 13–18 years, autism spectrum disorder VIQ >85}\) | Waitlist control: \(N = 11, M_{\text{age}} = 16 \text{ years (s.d. = 1.33 years)}\) | Allocation via computer-generated random sequence program | Score 14 or higher on BDI-II\(^{15}\) | Group CBT: ‘Exploring depression: cognitive behavior therapy to understand and cope with depression’,\(^{17}\) designed for individuals with Asperger syndrome 11 × 1-h sessions, 3–4 participants per group | 10 weeks | Measured pre- and post-treatment, and 4 and 12 weeks post-treatment; BDI-II,\(^{15}\) DASS\(^{45}\) and Emotion Regulation Questionnaire\(^{53}\) | No significant change in BDI-II score from pre- to post-intervention or across the treatment and control groups. Significant decrease in DASS depression scores for the treatment group when analysed independently of the waitlist control | Moderate |

WISC, Wechsler Intelligence Scale for Children; FSIQ, Full Scale Intelligence Quotient; CDI, Children’s Depression Inventory; M_{\text{age}}, mean age; BASC-2, Behavior Assessment System for Children, 2nd edition; CBT, cognitive–behavioural therapy; DASS, Depression, Anxiety and Stress Scales; ATQ, Automatic Thoughts Questionnaire; ASSQ, Anxious Self-Statements Questionnaire; PPV, Peabody Picture Vocabulary; VABS, Vineland Adaptive Behavior Scales; VIQ, verbal IQ; BDI-II, Beck Depression Inventory.
Multiple baseline design: One study employed an experimental multiple baseline across behaviours design with a 10-year-old male with borderline intellectual disability (Wechsler Intelligence Scale for Children-Revised IQ = 79). The intervention took place on an in-patient unit, using behavioural treatment to target behaviours deemed to be reflective of depression in the participant. This included ‘inappropriate body position’, lack of eye contact, poor speech quality and bland affect. Behavioural intervention involved specific skill training incorporating instruction, modeling, role-playing and feedback of a more appropriate response in place of the inappropriate behaviour, over 20-min sessions each day. Baseline was established over 8 days for all behaviours, followed by introduction of the behavioural treatment for the first two behaviours simultaneously (six sessions), the third behaviour (five sessions) and the final behaviour (nine sessions). Frequency of target behaviours was recorded during each session, with reductions in each target behaviour observed following the introduction of the intervention, and maintenance of improvements at 12-week follow-up. Although the study involved administration of a number of depression screening tools during their initial diagnostic process, these were not used to assess post-treatment outcomes.

Uncontrolled trials: Two studies were uncontrolled trials. One study was a case series with a pre–post design, reporting on existing patients seen in an in-patient setting. This study identified patients (N = 31) with an intellectual disability aged 3–16 years, diagnosed with depression according to the DSM-III. Gender was not reported. Treatment was described as the standard treatment used in the clinical setting. Individual psychotherapy was the primary treatment utilised, although frequency and duration of therapy were not specified. An unspecified number of participants were prescribed medication when it was clear the psychotherapy alone was not effective. The timing of the introduction of medication was not reported, and the impact was not considered in the reporting of outcomes. Outcomes were reported after approximately 6 months of treatment, before discharge from the facility. A total of 87% of patients (n = 27) were considered to have shown a clear clinical improvement by the time of discharge. However, a definition of clinical improvement was not reported, nor was the effect of medication.

The second pre–post design was an uncontrolled trial involving participants with autism and no co-occurring intellectual disability (n = 39, 82% male, mean age 10 years) to receive a structured intervention. Participants in this study undertook a 12-week group CBT programme targeting social competence skills. Depressive symptoms were measured at the beginning and at the end of the treatment programme, using the depression subscale score of the Behavior Assessment System for Children, a parent-report measure. No change was seen in depressive symptoms from the beginning to end of treatment, although improvements were seen in aggression, emotion control and autism symptoms.

Controlled trials: Three studies were controlled trials. One trial evaluated the effect of a lifestyle intervention, a physical exercise programme, specifically assisted cycling therapy (ACT), in a group of young people with Down syndrome (n = 49, 59% male, mean age 18.3 years, s.d. 4.1 years). ACT involved the use of a mechanical motor attached to a stationary exercise bicycle to increase the individual’s cycling rate above their preferred voluntary cycling rate. Participants were counterbalanced to one of two active treatment groups, ACT or voluntary cycling, although how the counterbalancing was achieved was not described, nor was it clear whether participants were randomised to each group. A no-cycling control group was recruited through convenience sampling, by advertising in local communities. There were no group differences at baseline in terms of gender, chronological age, receptive language ability, hours of sport per week or body mass index. However, the ACT group scored significantly higher on a measure of cognitive planning compared to both the voluntary and no cycling groups. Depression symptoms were measured both pre- and post-treatment, using the CDI, with greater improvements on CDI scores seen in the ACT group when compared with both the voluntary and no cycling groups at the end of the 8-week therapy.

The second controlled trial reported on the effect of a group CBT programme for young people with Asperger syndrome or autism without intellectual disability (n = 42, 72% male, mean age 20.6 years, s.d. 4.1). Participants were allocated to either treatment or waitlist control, according to alternating order of study enrolment (i.e., pseudo-randomisations). The 9-week CBT programme was developed with particular regard to the social difficulties often experienced by young people with autism. Depression was measured by the depression subscale of the Depression, Anxiety and Stress Scales (DASS) at pre-treatment, post-treatment and again at 3 and 9 months’ follow-up. There was no significant difference between the groups post-treatment. However, there was a significant decrease in DASS depression scores for those participants with scores in the clinical range at pre-treatment. These improvements were maintained at both 3 and 9 months’ follow-up.

The final controlled study also evaluated a group CBT programme for young people with autism with no intellectual disability (n = 23, 60% male, mean age, 15.75 years, s.d. 1.37). Participants were randomly allocated to either waitlist or control, via a computer-generated random sequence programme. The 10-week group CBT programme was designed specifically for young people with autism. Depression was measured with both the DASS depression subscale and the BDI-II at pre-treatment, post-treatment and at 4 and 12 weeks’ follow-up. The authors reported no significant change in BDI-II scores from pre- to post-treatment, although a significant decrease was seen in DASS depression scores for the treatment group.

Research questions 2 and 3: what are the experiences of young people and their families and treatments for depression, and what are the experiences of professionals in delivering treatment for depression?

No studies were identified that had a focus on evaluating the experiences of young people with intellectual disability and/or autism and their families in receiving psychological treatment for depression. Only two of the included studies reporting on treatments for depression also reported participant experience. Santomauro et al gathered feedback from 15 young people with autism during their final group booster session, as a group discussion. Fourteen out of 15 young people reported enjoying the programme, with the 15th participant still recommending the programme for its usefulness. Participants considered the group setting the most beneficial aspect of the CBT programme. Greig and MacKay briefly noted that the participant in their single case study felt that the intervention had worked for them in real-life situations.

No studies evaluated the professional or clinician experience of delivering treatment for depression to children and young people with intellectual disability and/or autism.

Risk of bias

Risk of bias was assessed for all studies. No studies were considered to have a low risk of bias. All of the clinical case reports (n = 4) were assessed as high risk of bias. Clinical case reports are inherently biased: they have a high risk of publication bias; they are
retrospective reports and subject to information bias in that they involve subjective interpretation by the author who is often the treating clinician; outcome assessment measures are often administered by the clinician; and causal relationships and generalisation are not possible because of the nature of describing treatment outcome for one individual, often leading to overinterpretation of results and treatment effectiveness. In addition to these overarching issues, the included clinical case reports had particular problems with outcome measures, including selecting inappropriate measures, not reporting how scores were calculated and not reporting on all outcomes as stated.

Of the quasi-experimental and experimental studies, four studies were rated to have a moderate risk of bias, including the multiple baseline design, and the remaining two rated as high risk of bias (both uncontrolled trials). Reasons for ratings of moderate and high risk of bias included no control group, no or poor randomisation when there was a control group, outcome measures administered by the clinician delivering treatment, use of outcome measures with unestablished psychometric properties in intellectual disability and/or autism, and not considering effects of confounding variables (e.g. medication).

**Discussion**

This systematic search identified 10 studies that evaluated psychological treatments for depression in children and young people with intellectual disability and/or autism. However, four of these were clinical case reports with a high risk of bias and thus are unable to directly inform a research evidence base to guide treatment. The remaining six studies included four studies with either a single case experimental design, an uncontrolled group design, or a controlled group design. The six experimental/quasi-experimental studies each focused on different treatments, different population groups, used different outcome measures for depression and were all rated with a moderate or high risk of bias. Therefore, no conclusions can be drawn with any confidence about the suitability or effectiveness of any particular psychological or psychosocial intervention for treating depression in children and young people with intellectual disability and/or autism. There was also essentially a complete lack of information about the experiences of young people or their families who received psychological intervention for depression, or the therapists who delivered the intervention.

**Study design**

High-quality, randomised controlled trials are essential to improve the evidence-base for effectiveness of these interventions. Only one of the three controlled trials employed adequate randomisation strategies, with the others allocating participants based on order of enrolment, or through counterbalancing, which was not thoroughly described. Future studies should focus on developing well-designed, randomised controlled trials to address this important gap in the literature.

In addition to the need for well-designed trials, future research should evaluate existing evidence-based psychological and psychosocial treatments for depression adapted specifically to meet the needs of children and young people with intellectual disability and/or autism. Although a range of psychological and psychosocial interventions were identified in this review, only two of the experimental studies reported that the intervention used had been adapted for young people with autism. Importantly, none of the interventions described had been adapted for young people with intellectual disability. Development of new interventions tailored specifically for this population is also important. New interventions should be developed and evaluated through pilot studies, and further trialled in randomised controlled trials. The role of a parent/caregiver as support or facilitator within psychological interventions should also be considered. This approach has been successfully demonstrated in interventions with adults with intellectual disability (for example, Jahoda et al). Particularly important in any adaptation or development of interventions is collaboration with the key stakeholders: young people with intellectual disability and/or autism, their families and the therapists delivering the interventions.

**Exclusion of intellectual disability**

Inclusion of children and young people with intellectual disability was extremely limited. Only four studies included participants with an intellectual disability, and six studies included participants with a diagnosis of Asperger syndrome or autism without co-occurring intellectual disability. No studies involved participants with both intellectual disability and autism, consistent with a recent meta-analysis demonstrating selection bias against participants with intellectual disability in autism research. The exclusion of young people with intellectual disability was particularly evident in the controlled trials, with only the physical exercise intervention, involving no cognitive component, including participants with intellectual disability. This is a significant gap in the literature in that we have limited evidence of effective interventions for depression in children with intellectual disability, despite knowledge that rates of mental health problems, and in particular, depression, are prevalent in this population.

**Outcome measures**

Outcome measures of depression and depression symptoms were inconsistent, and in some cases, not valid measures of depression. Although a number of studies used validated measures and screening tools for depression, including the Revised Children’s Anxiety and Depression Scale (RCADS) depression subscale, the HRS-D, the DASS Depression scale, the CDI-II and the BDI-II, others relied on subjective measurement such as clinical judgement, or changes in behaviour not necessarily indicative of depression. None of the depression measures used were developed or adapted for people with intellectual disability and/or autism. Further, selection of outcome measures was not suitable in all studies. For example, the DASS is a tool designed for use with a typically developing adult population, yet was used with children and young people as young as 13 years in these studies. Use of suitable depression outcome measures is critical for future studies to ensure effectiveness in treating depression presenting in children and young people with intellectual disability and/or autism. Some caregiver-report measures of depressive symptoms in children and young people with intellectual disability already exist, such as the Developmental Behavior Checklist and the Anxiety, Depression and Mood Scale, and could be used to assess change in depressive symptoms. Some research has used adapted versions of the CDI for young people with intellectual disability, and the Glasgow Depression Scale, for use with children and young people, could be considered in future research.

**Strengths and limitations**

The current review was conducted with strong methodological rigour, in line with PRISMA guidelines and following a pre-registered protocol. Strengths of this review include the broad definition...
of psychological and psychosocial therapies used, ensuring all relevant treatments and interventions were identified, the inclusion of all publication types, including theses, and no restrictions on date of publication. Non-English publications were excluded; however, two studies were identified from countries without English as a first language. A meta-analysis was not undertaken because of the small number of studies identified, their poor quality and moderate-to-high risk of bias.

Summary and future directions
This systematic review highlights a number of significant gaps in the literature for treatment of depression for children and young people with intellectual disability and/or autism. The lack of well-designed, randomised controlled trials was clear, as was the exclusion of young people with intellectual disability. The complete lack of research on psychological interventions for young people with intellectual disability was striking and concerning. Adaptation and development of specifically tailored psychological and psychosocial interventions for depression in children and young people with intellectual disability and/or autism, as well as measures of depression and depressive symptoms, is an essential next step in the research. Future research should also ensure accurate records of medication are taken and considered when interpreting the effectiveness of a psychological intervention.

Further, evaluating experiences of both receiving treatment for depression (children and parents) and delivering treatment (therapists and professionals) is paramount in ensuring that interventions, both existing, adapted and newly developed, meet the needs of the patient. Future research should ensure that families and professionals are consulted on the design of interventions and evaluations of their experiences are embedded within any study design.

It is important to note that these findings are not unique to the treatment of depression for children and young people with intellectual disability and/or autism. There is an absence of intervention research of any psychological treatments for any mental health disorder in this population. Further, children and young people with severe intellectual disability are a particularly vulnerable group, and often neglected in research of mental health problems and intervention. As highlighted in a recent systematic review, future research into psychological treatments for depression for children and young people with intellectual disability and/or autism should also be supported by the development of appropriate outcome measures of any mental health symptoms for this population.

References
1. Allerton LA, Welch V, Emerson E. Health inequalities experienced by children and young people with intellectual disabilities: a review of literature from the United Kingdom. J Intellect Disabil 2011; 15(4): 269–78.
2. Einfeld SL, Ellis LA, Emerson EM. Comorbidity of intellectual disability and mental disorder in children and adolescents: a systematic review. J Intellect Dev Disabil 2011; 36(2): 137–43.
3. Maliano C, Coutou S, Tracey D, Bouchard S, Lepage G, Morin AJ, et al. Prevalence of anxiety and depressive disorders among youth with intellectual disabilities: a systematic review and meta-analysis. J Affect Disord 2018; 236: 30–42.
4. Douma JC, Dekker MC, Verhulst FC, Koot HM. Self-reports on mental health problems of youth with moderate to borderline intellectual disabilities. J Am Acad Child Adolesc Psychiatry 2006; 45(10): 1224–31.
5. Emerson E, Hatton C. Mental health of children and adolescents with intellectual disabilities in Britain. Br J Psychiatry 2007; 191(4): 493–9.
6. DeFilippis M. Depression in children and adolescents with autism spectrum disorder. Children 2018; 5: 112.
7. Versevenooge L, Langdon PE. Psychological therapies for people with intellectual disabilities: a systematic review and meta-analysis. Res Dev Disabil 2013; 34(11): 4085–102.
8. McCabe M, McGillivray J, Newton DC. Effectiveness of treatment programmes for depression among adults with mild/moderate intellectual disability. J Intellect Disabil Res 2006, 50(4): 239–47.
9. National Institute for Health and Care Excellence (NICE). Mental Health Problems in People with Learning Disabilities: Prevention, Assessment and Management (NG54). NICE, 2016. (https://www.nice.org.uk/guidance/ng54).
10. National Institute for Health and Care Excellence (NICE). Depression in Children and Young People: Identification and Management (NG134). NICE, 2019. (https://www.nice.org.uk/guidance/ng134).
11. Danial JT, Wood JJ. Cognitive behavioral therapy for children with autism: review and considerations for future research. J Dev Behav Pediatr 2013; 34(9): 702–15.
12. Lang R, Regester A, Lauderdale S, Ashbaugh K, Haring A. Treatment of anxiety in autism spectrum disorders using cognitive behaviour therapy: a systematic review. Dev Neurorehabil 2010; 13(1): 53–63.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
14. Kovacs M. Children’s Depressive Inventory: Manual. Multi-Health Systems, 1992.
15. Beck AT, Steer RA, Brown GK. Beck Depression Inventory Manual. Psychological Corporation, 1996.
16. Cuthill FM, Espie CA, Cooper S. Development and psychometric properties of the Glasgow Depression Scale for people with a learning disability. Br J Psychiatry 2003; 182: 347–53.
17. Monash Centre for Health Research and Implementation. Evidence Synthesis Program Template for Critical Appraisal of a Randomised Controlled Trial. Monash Centre for Health Research and Implementation, 2014.
18. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute, 2009.
19. Blackmore R, Gray KM, Boyle JA, Fazel M, Ranaarina S, Fitzgerald G, et al. Systematic review and meta-analysis: the prevalence of mental illness in child and adolescent refugees and asylum seekers. J Am Acad Child Adolesc Psychiatry 2020; 59(6): 705–14.
20. Horner RH, Carr EG, Halle J, McGee G, Odom S, Wolery M. The use of single-subject research to identify evidence-based practice in special education. Except Child 2005; 71(2): 165–79.

Author contributions
K.M.G., K.P. and R.P.H. formulated the research questions. K.M.G., K.P., R.P.H. and G.A.M. designed the study. K.P. and L.A.C. carried out the database search. K.M.G., K.P., K.M.G., G.A.M. and R.P.H. collected and analysed the data. L.A.C., K.M.G., R.P.H., G.A.M. and K.P. wrote the manuscript or contributed to substantive reviews and revisions. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work.

Declaration of interest
None.

Funding
This research received no specific grant from any funding agency, commercial, or not-for-profit sectors. L.A.C. is supported by an Australian Government Research Training Program (RTP) Scholarship. K.P. is the recipient of a University of New South Wales Australia Science PhD Scholarship.
